Evidence map›Paper›PMID 25911748›Full record

ArticleJournal of immunology (Baltimore, Md. : 1950)2015

Viremic HIV Controllers Exhibit High Plasmacytoid Dendritic Cell-Reactive Opsonophagocytic IgG Antibody Responses against HIV-1 p24 Associated with Greater Antibody Isotype Diversification.

M Christian Tjiam, James P A Taylor, Mazmah A Morshidi, Lucy Sariputra, Sally Burrows, Jeffrey N Martin, Steven G Deeks, Dino B A Tan, Silvia Lee, Sonia Fernandez and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of immunology (Baltimore, Md. : 1950), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

M Christian TjiamSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia; Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia 6000, Australia;
James P A TaylorSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia;
Mazmah A MorshidiSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia;
Lucy SariputraSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia;
Sally BurrowsSchool of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6009, Australia;
Jeffrey N MartinDivision of Clinical Epidemiology, University of California, San Francisco, San Francisco, CA 94117;
Steven G DeeksSchool of Medicine, University of California, San Francisco, San Francisco, CA 94117;
Dino B A TanSchool of Medicine and Pharmacology, University of Western Australia, Perth, Western Australia 6009, Australia; Centre for Asthma, Allergy and Respiratory Research, Lung Institute of Western Australia, Perth, Western Australia 6009, Australia; and.
Silvia LeeSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia; Department of Microbiology and Infectious Diseases, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia 6000, Australia.
Sonia FernandezSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia;
Martyn A FrenchSchool of Pathology and Laboratory Medicine, University of Western Australia, Perth, Western Australia 6009, Australia; Department of Clinical Immunology, Royal Perth Hospital and PathWest Laboratory Medicine, Perth, Western Australia 6000, Australia; martyn.french@uwa.edu.au.
University of Western Australia · AURoyal Perth Hospital · AUUniversity of California, San Francisco · USInstitute for Respiratory Health · AU

Funding

Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT · 2011 to 2015
$29.5M
Why do Patients Develop KSU54CA190153 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KAMBUGU, ANDREW DDUNGU, MARTIN, JEFFREY N · 2014 to 2019
$3.6M
NCI NIH HHS U54 CA190153NIAID NIH HHS AI096109NIAID NIH HHS P30 AI027763NIAID NIH HHS R24 AI067039NIAID NIH HHS U19 AI096109
6 · The paper itself

Abstract

Identifying the mechanisms of natural control of HIV-1 infection could lead to novel approaches to prevent or cure HIV infection. Several studies have associated natural control of HIV-1 infection with IgG Abs against HIV-1 Gag proteins (e.g., p24) and/or production of IgG2 Abs against HIV-1 proteins. These Abs likely exert their effect by activating antiviral effector cell responses rather than virus neutralization. We hypothesized that an opsonophagocytic IgG Ab response against HIV-1 p24 that activates plasmacytoid dendritic cells (pDCs) through FcγRIIa would be associated with control of HIV and that this would be enhanced by Ab isotype diversification. Using the Gen2.2 pDC cell line, we demonstrated that pDC-reactive opsonophagocytic IgG Ab responses against HIV-1 p24 were higher in HIV controllers (HIV RNA < 2000 copies/ml) than noncontrollers (HIV RNA > 10,000 copies/ml), particularly in controllers with low but detectable viremia (HIV RNA 75-2000 copies/ml). Opsonophagocytic Ab responses correlated with plasma levels of IgG1 and IgG2 anti-HIV-1 p24 and, notably, correlated inversely with plasma HIV RNA levels in viremic HIV patients. Phagocytosis of these Abs was mediated via FcγRIIa. Isotype diversification (toward IgG2) was greatest in HIV controllers, and depletion of IgG2 from Ig preparations indicated that IgG2 Abs to HIV-1 p24 do not enhance phagocytosis, suggesting that they enhance other aspects of Ab function, such as Ag opsonization. Our findings emulate those for pDC-reactive opsonophagocytic Ab responses against coxsackie, picorna, and influenza viruses and demonstrate a previously undefined immune correlate of HIV-1 control that may be relevant to HIV vaccine development.

Indexed as

AIDS VaccinesCD4 Lymphocyte CountCD4-Positive T-LymphocytesCell LineDendritic CellsHIV-1HIV AntibodiesHIV Core Protein p24HIV InfectionsHumansImmunoglobulin GPhagocytosisReceptors, IgGRNA, ViralViremiaAIDS VaccinesFc gamma receptor IIAHIV AntibodiesHIV Core Protein p24Immunoglobulin GReceptors, IgGRNA, Viral

Identifiers

PMID25911748
PMCPMC4492937
OpenAlexW1572230997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.